Of 1010 patients with luminal ERBB2-negative breast cancer assigned to CALND in the SENOMAC trial (luminal cohort; median [range] age, 61 [34-90] years; 1006 [99.6%] female and 4 [0.4%] male), 138 (13.7%) had a high nodal burden (Table). Here, ERBB2 is linked to breast cancer.